- Home
- WRD vs CNTA Comparison
WRD vs CNTA Comparison
Compare WRD & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WRD
- CNTA
- Stock Information
- Founded
- WRD 2017
- CNTA 2020
- Country
- WRD China
- CNTA United Kingdom
- Employees
- WRD N/A
- CNTA N/A
- Industry
- WRD
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- WRD
- CNTA Health Care
- Exchange
- WRD NYSE
- CNTA Nasdaq
- Market Cap
- WRD 2.0B
- CNTA 1.8B
- IPO Year
- WRD 2024
- CNTA 2021
- Fundamental
- Price
- WRD $8.01
- CNTA $12.30
- Analyst Decision
- WRD Buy
- CNTA Strong Buy
- Analyst Count
- WRD 2
- CNTA 10
- Target Price
- WRD $22.00
- CNTA $26.11
- AVG Volume (30 Days)
- WRD 11.3M
- CNTA 628.0K
- Earning Date
- WRD 05-21-2025
- CNTA 05-20-2025
- Dividend Yield
- WRD N/A
- CNTA N/A
- EPS Growth
- WRD N/A
- CNTA N/A
- EPS
- WRD N/A
- CNTA N/A
- Revenue
- WRD $49,476,511.00
- CNTA N/A
- Revenue This Year
- WRD N/A
- CNTA N/A
- Revenue Next Year
- WRD $194.65
- CNTA N/A
- P/E Ratio
- WRD N/A
- CNTA N/A
- Revenue Growth
- WRD N/A
- CNTA N/A
- 52 Week Low
- WRD $6.03
- CNTA $7.75
- 52 Week High
- WRD $44.00
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- WRD N/A
- CNTA 40.97
- Support Level
- WRD N/A
- CNTA $11.88
- Resistance Level
- WRD N/A
- CNTA $14.39
- Average True Range (ATR)
- WRD 0.00
- CNTA 0.79
- MACD
- WRD 0.00
- CNTA -0.00
- Stochastic Oscillator
- WRD 0.00
- CNTA 18.68
About WRD WERIDE INC. SPON ADS EACH REP 3 CL A ORD SHS
WeRide Inc operates in the autonomous driving industry. The company has developed a universal autonomous driving technology platform that integrates full-stack software algorithms, modularized hardware solutions, and a cloud-based infrastructure platform. The company provides autonomous driving products and services from L2 to L4 vehicles. The products of the company includes Robotaxi, Robobus, Robovan, Robosweeper, and others. The company earns its revenue from the People's Republic of China.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.